Insmed’s brensocatib shows efficacy and safety in fibrosis bronchiectasis trial

Insmed (INSM) presented 11 new abstracts at the American Thoracic Society 2025 International Conference May 18-21 in San Francisco, including three prespecified subgroup analyses from the Phase 3 ASPEN trial of brensocatib in non-cystic fibrosis bronchiectasis, or NCFBE, signaling the consistency of efficacy and safety outcomes across diverse clinical profiles. Three prespecified subgroup analyses from ASPEN showed brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and reduced lung function decline compared with placebo with a similar safety profile as the overall trial in adolescents, patients regardless of maintenance use of macrolides, patients with high or low blood eosinophil counts at baseline. Insmed also presented a post-hoc analysis from ASPEN on lung function, health economics and outcomes research findings demonstrating the high burden of bronchiectasis on the healthcare system, as well as several other abstracts across the company’s portfolio. These showcased new findings from an expanded Phase 2 analysis for treprostinil palmitil inhalation powder in patients with pulmonary hypertension associated with interstitial lung disease. Also shared were real-world comparative outcomes for patients treated with Arikayce and data exploring longitudinal health status improvements following culture conversion in refractory Mycobacterium avium complex lung disease.